Tag: CR011
Glembatumumab Vedotin Does Not Meet Primary Endpoint in METRIC Study
The randomized, Phase IIb METRIC Study of glembatumumab vedotin, also known as CDX-011, an antibody-drug conjugate or ADC being developed by Celldex, compared to...
Glembatumumab vedotin Shows Encouraging anti-tumor Activity Checkpoint Inhibitor-refractory Metastatic Melanoma
Results from a phase II trial presented in a poster at the annual meeting of the European Society of Medical Oncology, held in Copenhagen,...
Studies Show Glembatumumab Vedotin to be Effective in a Wide Range...
During the annual meeting of the American Association for Cancer Research (AACR) being held April 16 - 20, 2016 in New Orleans, LA, Celldex...
